Gilead Sciences (GILD) PT Raised to $165 at Wells Fargo
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls after US-Iran talks signal easing supply risks
- Intel soars after Trump says Apple agreed to work with chipmaker on US production
- Apple CEO warns price hikes 'unavoidable' as chip costs bite - WSJ
- Wall Street scrambles to lift Micron price targets ahead of earnings
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Gilead Sciences (GILD) PT Raised to $162 at BofA Securities
February 11, 2026 8:36 AM ESTBofA Securities analyst Tim Anderson raised the price target on Gilead Sciences (NASDAQ: GILD) to $162.00 (from $154.00) while maintaining a Buy rating.
The analyst comments "GILD reported strong 4Q product revenues of $7.9bn ahead of Street estimates (BofA: +4%, cons: +4%) driven by demand outperformance from... More
